The information gathered so far indicated that miR‐181a promoted angiogenesis in CRC through targeting SRCIN1 to promote the SRC/VEGF signaling pathway.10 Previous studies have presented that the inhibition of miR‐181a expression may restrain CRC cell proliferation via the signaling of PTEN/Akt pathway.11 Epigenetic silencing of miR‐181b may lead to tumorigenicity in CRC by targeting RASSF1A.12 Meanwhile, previous studies have reported that miR‐181a and miR‐181b were expressed abnormally in CRC tissue, and may be associated with unfavorable clinical outcome. The gene discussed is RASSF1; the disease is colorectal carcinoma.